HK Stock Market Move | Lithium mining stocks rose in intraday trading with Tianqi Lithium Corporation (09696) and Ganfeng Lithium Group (01772) both up over 5%.
Lithium mining stocks rose during trading session. As of the time of writing, Tianqi Lithium (09696) rose by 5.11% to HKD 45.24, while Ganfeng Lithium (01772) rose by 5.28% to HKD 56.85.
Intraday rise in lithium mining stocks, as of the time of writing, Tianqi Lithium Corporation (09696) rose by 5.11% to 45.24 Hong Kong dollars; Ganfeng Lithium Group (01772) rose by 5.28% to 56.85 Hong Kong dollars.
On the news front, a CITIC SEC research report pointed out that since May 2026, demand concerns and inventory changes have suppressed lithium price performance. However, the bank expects the tight supply-demand situation to not reverse in the short term, with lithium prices still expected to strengthen in the second half of 2026, maintaining a target price forecast of 25,000 yuan per ton. It is recommended to pay attention to the opportunities for portfolio adjustment after the sector reshuffles.
Sinosteel Futures believes that Australia's Greenbushes has lowered its annual production by 11%, with Core's resumption of shipments to the fourth quarter slower than market expectations; the internal unrest in Mali, Africa, although not directly affecting local lithium production, still presents uncertainty as the situation has not yet calmed down; the slow progress in the restart of the Wopstall mine or the delay to the fourth quarter, as well as the expected suspension of production at other muscovite mines in Jiangxi, indicate a reality and expectation of reduced supply. On the demand side, downstream production in June continues to hit record highs, with further strengthening of demand in June expected to accelerate destocking against the backdrop of industry destocking in May.
Related Articles

HK Stock Market Move | CISI FIN(06058) surged nearly 8% with year-on-year net profit after tax increasing by over 50% last year. Its China core asset fund has continued to perform exceptionally well.

A 40% premium! GlaxoSmithKline plc Sponsored ADR (GSK.US) plans to acquire Nuvalent (NUVL.US) for $10.6 billion, stepping up its presence in the cancer drug sector.

Yamato: Increased visibility of AI monetization in Chinese technology stocks, prefer TENCENT (00700) and others.
HK Stock Market Move | CISI FIN(06058) surged nearly 8% with year-on-year net profit after tax increasing by over 50% last year. Its China core asset fund has continued to perform exceptionally well.

A 40% premium! GlaxoSmithKline plc Sponsored ADR (GSK.US) plans to acquire Nuvalent (NUVL.US) for $10.6 billion, stepping up its presence in the cancer drug sector.

Yamato: Increased visibility of AI monetization in Chinese technology stocks, prefer TENCENT (00700) and others.






